{
    "clinical_study": {
        "@rank": "8487", 
        "arm_group": {
            "arm_group_label": "Treatment (benzoylphenylurea)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects and best dose of benzoylphenylurea in\n      treating patients with advanced cancer. Drugs used in chemotherapy use different ways to\n      stop tumor cells from dividing so they stop growing or die"
        }, 
        "brief_title": "Benzoylphenylurea in Treating Patients With Advanced Cancer", 
        "condition": "Unspecified Adult Solid Tumor, Protocol Specific", 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the dose-limiting toxicity and the maximum tolerated dose of benzoylphenylurea\n      in patients with advanced malignancy.\n\n      II. Determine the pharmacokinetics of this drug in these patients.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in\n      the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive\n      escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined.\n      The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience\n      dose-limiting toxicity.\n\n      PROJECTED ACCRUAL: A total of 3-30 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed malignancy\n\n               -  Metastatic or unresectable\n\n               -  No standard curative or palliative measures exist or are ineffective\n\n          -  Brain metastases allowed provided 1 of the following criteria is met:\n\n               -  Lesions were previously treated with surgery, radiotherapy, or chemotherapy AND\n                  are currently asymptomatic AND no steroid therapy or antiseizure medication\n                  within the past 2 weeks\n\n               -  Untreated, asymptomatic metastases AND no requirement for steroid therapy or\n                  antiseizure medication\n\n          -  Performance status - ECOG 0-2\n\n          -  More than 12 weeks\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n          -  Bilirubin normal\n\n          -  SGOT/SGPT no greater than 2.5 times upper limit of normal\n\n          -  Albumin at least 3.0 mg/dL\n\n          -  Creatinine normal\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  No symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia\n\n          -  No prior allergic reactions to compounds of similar chemical or biologic composition\n             to benzoylphenylurea\n\n          -  No neuropathy greater than grade 1\n\n          -  No other uncontrolled medical or psychiatric illness that would preclude study\n             compliance\n\n          -  No ongoing or active infection\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  Prior immunotherapy allowed\n\n          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)\n             and recovered\n\n          -  At least 2 weeks since steroids for CNS disease\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  Prior surgery allowed\n\n          -  At least 2 weeks since antiseizure medications for CNS disease\n\n          -  More than 7 days since prior CYP3A4 or CYP2D6 inhibitors\n\n          -  More than 7 days since prior CYP3A4 inducers\n\n          -  No concurrent CYP3A4 or CYP2D6 inhibitors\n\n          -  No concurrent CYP3A4 inducers\n\n          -  No other concurrent investigational agents\n\n          -  No concurrent combination anti-retroviral therapy for HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010205", 
            "org_study_id": "NCI-2012-02375", 
            "secondary_id": [
                "UMGCC 0038", 
                "U01CA069854", 
                "CDR0000068455"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (benzoylphenylurea)", 
                "description": "Given orally", 
                "intervention_name": "benzoylphenylurea", 
                "intervention_type": "Drug", 
                "other_name": "BPU"
            }, 
            {
                "arm_group_label": "Treatment (benzoylphenylurea)", 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21201-1595"
                }, 
                "name": "University of Maryland Greenebaum Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial Of Benzoylphenylurea (NSC#639829) In Advanced Malignancy", 
        "overall_official": {
            "affiliation": "University of Maryland Greenebaum Cancer Center", 
            "last_name": "Martin Edelman", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum-tolerated dose (MTD) defined as the highest dose level where 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) as assessed by CTCAE version 3.0", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "DLT defined as grade 3 or worse non-hematologic and sustained (> 5 days) grade 3 hematologic toxicity or grade 4 hematologic toxicity of any duration, and the moderate toxicity is grade 2 toxicity as assessed by CTCAE version 3.0", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Relationships between drug exposure and toxicity, efficacy, and biological endpoints will be explored using univariate and multivariate analysis techniques.", 
                "measure": "Pharmacokinetics of benzoylphenylurea", 
                "safety_issue": "No", 
                "time_frame": "At baseline, at 0.5, 1.0, 1.5, 2, 4, 6, 8, 24, 48, 72, and 96 hours (weeks 1 and 6)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010205"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate will be evaluated for all patients with measurable disease and will be obtained by dividing the total number of responses by all patients with measurable disease and reported with 95% confidence intervals.", 
                "measure": "Response (complete and partial response) rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 years"
            }, 
            {
                "description": "The median and landmark survivals will be estimated utilizing the Kaplan- Meier method.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "From the date of first treatment until death or last follow-up, assessed up to 7 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013", 
        "why_stopped": "Administratively complete."
    }, 
    "geocoordinates": {
        "University of Maryland Greenebaum Cancer Center": "39.29 -76.612"
    }
}